Cynosure To Host Investor Event To Introduce SculpSure, the World's First Hyperthermic Aesthetic Laser Treatment For Non-Invasive Fat Reduction

WESTFORD, Mass., Sept. 3, 2015 /PRNewswire/ -- Cynosure, Inc. (NASDAQ: CYNO), a leader in laser- and light-based aesthetic treatments, today announced that the Company will host an investor event in New York City on Tuesday, September 15 to introduce SculpSure, the only FDA-cleared hyperthermic laser treatment for non-invasive fat reduction. The Company will provide a live webcast of the event presentations from approximately 10:00 a.m. to 12:30 p.m. (ET).

Cynosure Chairman and Chief Executive Officer Michael Davin, President and Chief Financial Officer Timothy Baker and Executive Vice President of Worldwide Sales Douglas Delaney will host the event. In addition, the Company is honored to have as a presenter Bruce E. Katz, M.D., Director of the Cosmetic Surgery & Laser Clinic at Mount Sinai Medical Center and Director of the Juva Skin & Laser Center in New York.

The event will highlight Cynosure's proprietary hyperthermic laser technology and the global market opportunity for SculpSure as well as the Company's business model, distribution plans and marketing strategy. Dr. Katz will detail the clinical experience with SculpSure and demonstrate the treatment protocol. 

The live webcast will be available on the "Investors" section of the Company's website, www.cynosure.com. For those unable to listen to the live presentations, the event will be archived and available on the Company's website for 90 days.

About Cynosure, Inc.
Cynosure designs, manufactures and markets medical devices for aesthetic procedures and precision surgical applications worldwide. The Company's products enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve vaginal health. Cynosure also markets radiofrequency energy sourced medical devices for precision surgical applications such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology. Cynosure's product portfolio is composed of a broad range of energy sources including Alexandrite, diode, Nd:YAG, picosecond, pulse dye, Q-switched lasers, intense pulsed light and radiofrequency technology. Cynosure sells its products globally under the Cynosure, Palomar, ConBio and Ellman brand names through a direct sales force in the United States, Canada, Mexico, France, Germany, Spain, the United Kingdom, Australia, China, Japan and Korea, and through international distributors in approximately 120 other countries.  For corporate or product information, visit Cynosure's website at www.cynosure.com.

Contact  
Scott Solomon  
Vice President  
Sharon Merrill Associates   
617-542-5300 
cyno@investorrelations.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cynosure-to-host-investor-event-to-introduce-sculpsure-the-worlds-first-hyperthermic-aesthetic-laser-treatment-for-non-invasive-fat-reduction-300137567.html

SOURCE Cynosure, Inc.